INR 5104.95
(-0.72%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 2.56 Billion INR | -26.89% |
2022 | 3.5 Billion INR | 26.36% |
2021 | 2.77 Billion INR | -1.85% |
2020 | 2.82 Billion INR | 4.6% |
2019 | 2.7 Billion INR | 23.11% |
2018 | 2.19 Billion INR | -14.97% |
2017 | 2.57 Billion INR | 19.76% |
2016 | 2.15 Billion INR | 21.41% |
2015 | 1.77 Billion INR | 15.27% |
2014 | 1.53 Billion INR | 22.91% |
2013 | 1.25 Billion INR | 13.22% |
2012 | 1.1 Billion INR | 23.53% |
2011 | 895.4 Million INR | 7.16% |
2010 | 835.6 Million INR | -17.16% |
2009 | 1 Billion INR | -7.58% |
2008 | 1.09 Billion INR | 63.8% |
2007 | 666.3 Million INR | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 Q4 | 2.56 Billion INR | 0.0% |
2023 FY | 2.56 Billion INR | -26.89% |
2023 Q2 | 2.71 Billion INR | 0.0% |
2023 Q1 | - INR | -100.0% |
2022 Q3 | - INR | -100.0% |
2022 Q1 | - INR | -100.0% |
2022 FY | 3.5 Billion INR | 26.36% |
2022 Q4 | 3.5 Billion INR | 0.0% |
2022 Q2 | 3.45 Billion INR | 0.0% |
2021 Q2 | 2.61 Billion INR | 0.0% |
2021 Q1 | - INR | -100.0% |
2021 Q3 | - INR | -100.0% |
2021 Q4 | 2.77 Billion INR | 0.0% |
2021 FY | 2.77 Billion INR | -1.85% |
2020 Q2 | 2.06 Billion INR | 0.0% |
2020 Q4 | 2.82 Billion INR | 0.0% |
2020 Q3 | - INR | -100.0% |
2020 FY | 2.82 Billion INR | 4.6% |
2019 FY | 2.7 Billion INR | 23.11% |
2018 FY | 2.19 Billion INR | -14.97% |
2018 Q2 | 2.19 Billion INR | 0.0% |
2018 Q4 | 2.29 Billion INR | 0.0% |
2017 Q2 | 2.57 Billion INR | 0.0% |
2017 FY | 2.57 Billion INR | 19.76% |
2017 Q4 | 2.53 Billion INR | 0.0% |
2016 FY | 2.15 Billion INR | 21.41% |
2016 Q4 | 2.27 Billion INR | 0.0% |
2016 Q2 | 2.15 Billion INR | 0.0% |
2015 FY | 1.77 Billion INR | 15.27% |
2015 Q2 | 1.77 Billion INR | 0.0% |
2015 Q4 | 1.9 Billion INR | 0.0% |
2014 Q4 | 1.83 Billion INR | 0.0% |
2014 Q2 | 1.53 Billion INR | 0.0% |
2014 FY | 1.53 Billion INR | 22.91% |
2013 Q4 | 1.37 Billion INR | 0.0% |
2013 Q2 | 1.25 Billion INR | 0.0% |
2013 FY | 1.25 Billion INR | 13.22% |
2012 FY | 1.1 Billion INR | 23.53% |
2012 Q2 | 1.1 Billion INR | 0.0% |
2012 Q4 | 1.27 Billion INR | 0.0% |
2011 FY | 895.4 Million INR | 7.16% |
2011 Q4 | 1.99 Billion INR | 0.0% |
2011 Q2 | 895.4 Million INR | 0.0% |
2010 FY | 835.6 Million INR | -17.16% |
2009 FY | 1 Billion INR | -7.58% |
2008 FY | 1.09 Billion INR | 63.8% |
2007 FY | 666.3 Million INR | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Alembic Pharmaceuticals Limited | 16.27 Billion INR | 84.262% |
Aurobindo Pharma Limited | 152.2 Billion INR | 98.317% |
Glenmark Life Sciences Limited | 5.18 Billion INR | 50.565% |
Granules India Limited | 22.95 Billion INR | 88.842% |
Indoco Remedies Limited | 10.34 Billion INR | 75.236% |
Achyut Healthcare Limited | 2.01 Million INR | -127132.986% |
Ajanta Pharma Limited | 10.71 Billion INR | 76.087% |
Alkem Laboratories Limited | 48.6 Billion INR | 94.731% |
Alpa Laboratories Limited | 307.12 Million INR | -733.936% |
Brooks Laboratories Limited | 248.6 Million INR | -930.245% |
AstraZeneca Pharma India Limited | 3.66 Billion INR | 30.043% |
Bajaj HealthCare Limited | 4.86 Billion INR | 47.383% |
Bliss GVS Pharma Limited | 2.1 Billion INR | -21.45% |
Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 97.606% |
Eris Lifesciences Limited | 38.26 Billion INR | 93.307% |
FDC Limited | 3.7 Billion INR | 30.95% |
Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 96.066% |
Gufic Biosciences Limited | 5.59 Billion INR | 54.263% |
Ind-Swift Laboratories Limited | 2.28 Billion INR | -11.869% |
Ipca Laboratories Limited | 33.74 Billion INR | 92.41% |
Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -763.054% |
Krebs Biochemicals & Industries Limited | 2.97 Billion INR | 13.878% |
Lasa Supergenerics Limited | 541.92 Million INR | -372.612% |
Laurus Labs Limited | 42.71 Billion INR | 94.004% |
Lupin Limited | 96.23 Billion INR | 97.339% |
Mankind Pharma Limited | 23.87 Billion INR | 89.272% |
Medicamen Biotech Limited | 940.36 Million INR | -172.362% |
Medico Remedies Limited | 438.24 Million INR | -484.423% |
Megasoft Limited | 1.85 Billion INR | -38.208% |
NATCO Pharma Limited | 10.53 Billion INR | 75.682% |
Piramal Pharma Limited | 74 Billion INR | 96.539% |
RPG Life Sciences Limited | 1.38 Billion INR | -85.567% |
Sigachi Industries Limited | 2.53 Billion INR | -1.183% |
Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 98.605% |
Suven Pharmaceuticals Limited | 2.03 Billion INR | -25.905% |
Syncom Formulations (India) Limited | 1.16 Billion INR | -119.806% |
Unichem Laboratories Limited | 8.06 Billion INR | 68.26% |
Wanbury Limited | 3.15 Billion INR | 18.834% |
Windlas Biotech Limited | 1.76 Billion INR | -45.3% |
ZIM Laboratories Limited | 2.08 Billion INR | -23.09% |
Zydus Lifesciences Limited | 71.79 Billion INR | 96.432% |
Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | 34.208% |
Divi's Laboratories Limited | 18.99 Billion INR | 86.513% |
Hester Biosciences Limited | 3.59 Billion INR | 28.751% |
Amrutanjan Health Care Limited | 783.82 Million INR | -226.757% |
Bal Pharma Limited | 2.51 Billion INR | -1.988% |
Strides Pharma Science Limited | 37.68 Billion INR | 93.203% |
Venus Remedies Limited | 1.39 Billion INR | -83.889% |
Aarti Pharmalabs Limited | 8.25 Billion INR | 68.958% |
Nectar Lifesciences Limited | 11.21 Billion INR | 77.169% |
Shilpa Medicare Limited | 12.93 Billion INR | 80.196% |
Aarti Drugs Limited | 11.5 Billion INR | 77.736% |
IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | 59.532% |
Suven Life Sciences Limited | 148.62 Million INR | -1623.31% |
Ind-Swift Limited | 13.45 Billion INR | 80.962% |
Valiant Laboratories Limited | 1.05 Billion INR | -142.02% |
J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | 76.081% |
Solara Active Pharma Sciences Limited | 14.14 Billion INR | 81.892% |
Themis Medicare Limited | 1.88 Billion INR | -35.692% |
Hikal Limited | 12.99 Billion INR | 80.291% |
Torrent Pharmaceuticals Limited | 82.05 Billion INR | 96.878% |
Sequent Scientific Limited | 8.27 Billion INR | 69.046% |
Novartis India Limited | 1.8 Billion INR | -42.202% |
Wockhardt Limited | 39.87 Billion INR | 93.576% |
Jubilant Pharmova Limited | 61.27 Billion INR | 95.82% |
Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -786.845% |
Neuland Laboratories Limited | 5.49 Billion INR | 53.421% |
Morepen Laboratories Limited | 4.45 Billion INR | 42.571% |
Kilitch Drugs (India) Limited | 643.88 Million INR | -297.774% |
Mangalam Drugs & Organics Limited | 1.97 Billion INR | -29.595% |